27. Hernán MA, Zhang SM, Rueda-deCastro AM, Colditz GA, Speizer FE, Ascherio A. Cigarette smoking and the incidence of Parkinson's disease in two prospective studies. *Ann Neurol* 2001;50:780–786.
28. Palmatier MA, Kang AM, Kidd KK. Global variation in the frequencies of functionally different catechol-*O*-methyltransferase alleles. *Biol Psychiatry* 1999;46:557–567.
29. Grimsby J, Toth M, Chen K, et al. Increased stress response and beta-phenylethamine in MAOB-deficient mice. *Nat Genet* 1997;17:206–210.
30. Fowler CJ, Wiberg Å, Oreland L, Marcusson J, Winblad B. The effect of age on the activity and molecular properties of human brain monoamine oxidase. *J Neural Transm* 1980;49:1–20.
31. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. *N Engl J Med* 1989;321:1364–1371.
32. Tetrad JW, Langston W. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. *Science* 1989;245:519–522.
33. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progress of Parkinson's disease. *Ann Neurol* 1995;38:771–777.
34. Riederer P, Konradi C, Hebenstreit G, Youdim MBH. Neurochemical perspectives to the function of monoamine oxidase. *Acta Neurol Scand* 1989;126:41–45.
35. Yong VW, Paerry TL. Monoamine oxidase B, smoking, and Parkinson's disease. *J Neurol Sci* 1986;72:265–272.
36. Steventon GB, Sturman SG, Heafield MTE, Waring RH, Napier J, Williams AC. Platelet monoamine oxidase-B activity in Parkinson's disease [Parkinson's Disease and Dementia Section]. *J Neural Transm* 1989;1:255–261.
37. Steventon G, Humfrey C, Sturman S, Waring RH, Williams AC. Monoamine oxidase B and Parkinson's disease. *Lancet* 1990;335:180.
38. Garpenstrand H, Ekblom J, Forslund K, Rylander G, Oreland L. Platelet monoamine oxidase activity is related to MAOB intron 13 genotype. *J Neural Transm* 2000;107:523–530.
39. Müller MM, Gerster T, Schaffner W. Enhancer sequences and the regulation of gene transcription. *Eur J Biochem* 1988;176:485–495.
40. Chen Z-Y, Powell JF, Hsu Y-PP, Breakefield O, Craig IW. Organization of the human monoamine oxidase genes and long-range physical mapping around them. *Genomics* 1992;14:75–82.
41. Shih JC, Zhu Q-S, Grimsby J, Chen K. Identification of human monoamine oxidase (MAO) A and B gene promoters. *J Neural Transm Suppl* 1994;41:27–33.
42. Nutt JG. Catechol-*O*-methyltransferase inhibitors for treatment of Parkinson's disease. *Lancet* 1998;351:1221–1222.
43. Lee MS, Lyoo CH, Ulmanen I, Syvänen A-C, Rinne JO. Genotypes of catechol-*O*-methyltransferase and response to levodopa treatment in patients with Parkinson's disease. *Neurosci Lett* 2001;298:131–134.
44. Takkouche B, Cadarso-Suárez C, Spiegelman D. An evaluation of old and new tests of heterogeneity in meta-analysis in epidemiologic research. *Am J Epidemiol* 1999;150:206–215.
45. Costa-Bouzas J, Takkouche B, Cadarso-Suárez C, Spiegelman D. HEpiMA. A software for the identification of heterogeneity in meta-analysis. *Comput Methods Programs Biomed* 2001;64:101–107.
46. Tan EK, Khajavi M, Thornby JI, Nagamitsu S, Jankovic J, Ashizawa T. Variability and validity of polymorphism association studies in Parkinson's disease. *Neurology* 2000;55:533–538.

Neuro Images

Figure. MRI with gadolinium of the cervico-thoracic-lumbar spine. T1-weighted sagittal (A) and axial (B) images demonstrate the presence of epidural fat from T1 to T9 and thecal sac compression.

Epidural lipomatosis

Mirela Draganescu, MD, Matthew Daka, MD,
Ramon Manon-Espaillat, MD, Philadelphia, PA

A 60-year-old obese woman with diabetes, hypertension, and progressive bilateral leg weakness over 2 years was admitted for a complicated urinary tract infection. She had hyperreflexic lower extremities with 3/5 strength and bilateral Babinski at presentation. Within 24 hours the patient became paraplegic with areflexia, 0/5 leg strength, preserved proprioception, and a T7 sensory level. MRI with gadolinium (see figure) showed epi-

dural lipomatosis from T1 to T9 causing anterior thecal sac displacement and spinal canal narrowing. After laminectomy with excision of the epidural fat and subsequent rehabilitation, motor function improved to baseline. Epidural lipomatosis should be considered when evaluating obese patients with progressive paraparesis. The patient had no evidence of Cushing disease or chronic steroid use, which are known risk factors.¹ Abrupt paraplegia is atypical for this disease process.

1. Robertson SC, Traynelis VC, Follett KA, Menezes AH. Idiopathic spinal epidural lipomatosis. *Neurosurgery* 1997;41:68–75.

Neurology[®]

Epidural lipomatosis

Mirela Draganescu, Matthew Daka and Ramon Manon-Espaillet

Neurology 2002;58;1387

DOI 10.1212/WNL.58.9.1387

This information is current as of May 14, 2002

Updated Information & Services

including high resolution figures, can be found at:
<http://n.neurology.org/content/58/9/1387.full>

References

This article cites 1 articles, 0 of which you can access for free at:
<http://n.neurology.org/content/58/9/1387.full#ref-list-1>

Subspecialty Collections

This article, along with others on similar topics, appears in the following collection(s):

All Spinal Cord

http://n.neurology.org/cgi/collection/all_spinal_cord

Endocrine

<http://n.neurology.org/cgi/collection/endocrine>

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:

http://www.neurology.org/about/about_the_journal#permissions

Reprints

Information about ordering reprints can be found online:

<http://n.neurology.org/subscribers/advertise>

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright . All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.